Abstract:Background: TNM stage alone cannot accurately predict the recurrence risk after curative resection of colorectal cancer (CRC) and the benefit of adjuvant chemotherapy for patients with stage II CRC. We assessed the value of prothrombin time (PT) and carcinoembryonic antigen (CEA) levels in recurrence prediction and whether the combination of PT and CEA levels and TNM stage can improve the accuracy in predicting postoperative recurrence of CRC.Methods: The coagulation indexes and tumor markers of 451 patients with CRC were analyzed retrospectively. Log-rank test, Cox proportional hazard regression model and Kaplan-Meier survival curve were used to analyze the value of these indexes in predicting postoperative recurrence in different TNM stage subgroups.Results: Preoperatively elevated levels of PT (≥12.65s) and CEA (≥ 10.175ng/ml) were independent factors affecting postoperative recurrence of CRC (p < 0.05 and p < 0.01, respectively). 451 CRC patients were divided into three groups according to preoperative levels of PT and CEA. The 5-year cumulative recurrence rate (CRR) and recurrence-free survival (RFS) differed significantly among the High-risk (PT ≥12.65s and CEA≥ 10.175ng/ml), Middle-risk (PT ≥12.65s or CEA≥ 10.175ng/ml), and Low-risk (PT < 12.65s and CEA < 10.175ng/ml) groups (p < 0.001). Patients in the High-risk group even have a significantly higher 5-year CRR and shorter RFS than those in TNM stage III (5-year CRR: 67.2% vs 48.7%, p < 0.001; RFS: 33.7 months vs 39.7 months, p < 0.001). PT and CEA as biomarkers for prognostic stratification showed that, in the subgroup of stage III, the 5-year CRR of the High-risk group was more than twice that of the Low-risk group (71.1% vs 31.8%, p < 0.001), and the RFS was 16.1 months shorter than that of the Low-risk group (30.1 vs 46.2, p < 0.001). In the subgroup of early-stage (stage I and II), the 5-year CRR in the High-risk group was more than 3 times higher than that in the Low-risk group (61.5%vs 18.4%; p < 0.001), and even higher than that in stage IIIA and B (61.5% vs 36.4%; p < 0.001) and similar to that in stage IIIC (61.5% vs 62.9%; p >0.05); moreover, the RFS of the High-risk group of early-stage was notably shorter than that of the Low-risk group (38.9 vs 53 months; p < 0.001) and even that of IIIA and B (38.9 vs 45.2 months; p < 0.05).Conclusion: Preoperatively elevated levels of PT and CEA were reliable predictors of postoperative high recurrence in CRC patients. Incorporation of PT and CEA levels to a recurrence prediction model with TNM stage can precisely identify a subgroup of CRC patients with -risk of recurrence in stage I-III, especially the risk of recurrence population in stage I and II.Funding Information: This work was supported by the National Natural Science Foundation of China (81502039), the Natural Science Foundation of Fujian Province (2016J01616 and 2020J011214), the Health and Family Planning Commission of Fujian Province for Youth Research Project (2015-2-49), the Scientific Research Foundation for Returned Scholars from Ministry of Human Resources and Social Security (2015142), and the Digestive Center of Xiamen University Foundation.Declaration of Interests: The authors had declared no conflict of interest.Ethics Approval Statement: This study was approved by the Ethics Review Committee of Zhongshan Hospital of Xiamen University and the informed consent of the patients was obtained.

Clinical significance of the post/preoperative anti-p53 antibody ratio in predicting the prognosis of patients with colorectal cancer after curative surgery and its usefulness in combination with carcinoembryonic antigen

Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA

Clinical Significance of P53 Expression in Colorectal Cancer Patients

Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.

Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival

The prognostic value of p53 positive in colorectal cancer: A retrospective cohort study.

Pre-operative to post-operative serum carcinoembryonic antigen ratio is a prognostic indicator in colorectal cancer.

Clinical Significances of Positive Postoperative Serum CEA and Post-preoperative CEA Increment in Stage II and III Colorectal Cancer: A Multicenter Retrospective Study

Combined Detection of the Expression of Nm23-H1 and P53 is Correlated with Survival Rates of Patients with Stage Ii and Iii Colorectal Cancer

Preoperative Serum Carcinoembryonic Antigen, Carbohydrate Antigen19-9 and Carbohydrate Antigen 125 as Prognostic Factors for Recurrence-free Survival in Colorectal Cancer

The Complete Loss of p53 Expression Uniquely Predicts Worse Prognosis in Colorectal Cancer

Postoperative Carcinoembryonic Antigen (CEA) Levels Predict Outcomes after Resection of Colorectal Cancer in Patients with Normal Preoperative CEA Levels.

Effect of KRAS Mutations and P53 Expression on the Postoperative Prognosis of Patients with Colorectal Cancer.

Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer

Clinical Significance of and Predictive Risk Factors for the Postoperative Elevation of Carcinoembryonic Antigen in Patients with Non-Metastatic Colorectal Cancer

Prognostic Significance of Preoperative and Postoperative Evaluation of Combined Tumor Markers for Patients With Colon Cancer

Clinical utility of the carcinoembryonic antigen level in patients with stage III colon cancer after surgery and adjuvant chemotherapy

Combining PT and CEA Levels with the TNM Stage System to Identify Postoperative Recurrence Patients with Stage I-III Colorectal Cancer

Prognostic value of the postoperative carcinoembryonic antigen level in colorectal cancer: A meta‐analysis

Prognostic Significance of Preoperative Serum Carcinoembryonic Antigen Varies with Lymph Node Metastasis Status in Colorectal Cancer

Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients